JP2011178786A - 粘膜保護用医薬としてのホスファチジルコリン - Google Patents
粘膜保護用医薬としてのホスファチジルコリン Download PDFInfo
- Publication number
- JP2011178786A JP2011178786A JP2011050079A JP2011050079A JP2011178786A JP 2011178786 A JP2011178786 A JP 2011178786A JP 2011050079 A JP2011050079 A JP 2011050079A JP 2011050079 A JP2011050079 A JP 2011050079A JP 2011178786 A JP2011178786 A JP 2011178786A
- Authority
- JP
- Japan
- Prior art keywords
- colitis
- phosphatidylcholine
- mdr3
- treatment
- colon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 title claims abstract description 37
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 210000004877 mucosa Anatomy 0.000 title abstract description 8
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 206010061218 Inflammation Diseases 0.000 claims abstract description 12
- 230000004054 inflammatory process Effects 0.000 claims abstract description 12
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 10
- 210000000664 rectum Anatomy 0.000 claims abstract description 9
- 230000003111 delayed effect Effects 0.000 claims abstract description 8
- 230000001681 protective effect Effects 0.000 claims abstract description 8
- 108090000743 multidrug resistance protein 3 Proteins 0.000 claims description 36
- 102000004233 multidrug resistance protein 3 Human genes 0.000 claims description 36
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 28
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 27
- 210000003405 ileum Anatomy 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 206010009887 colitis Diseases 0.000 claims description 14
- 210000001072 colon Anatomy 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 208000011231 Crohn disease Diseases 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 11
- 206010009944 Colon cancer Diseases 0.000 claims description 9
- 239000013543 active substance Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 239000000523 sample Substances 0.000 claims description 7
- 201000003146 cystitis Diseases 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- 208000004232 Enteritis Diseases 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 229940088710 antibiotic agent Drugs 0.000 claims description 5
- 238000001574 biopsy Methods 0.000 claims description 5
- 238000002405 diagnostic procedure Methods 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 230000002458 infectious effect Effects 0.000 claims description 4
- 210000003097 mucus Anatomy 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 210000001198 duodenum Anatomy 0.000 claims description 3
- 210000003238 esophagus Anatomy 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 3
- 210000003384 transverse colon Anatomy 0.000 claims description 3
- 101150071913 MDR3 gene Proteins 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 208000019399 Colonic disease Diseases 0.000 claims 1
- 206010058838 Enterocolitis infectious Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 102000040945 Transcription factor Human genes 0.000 claims 1
- 108091023040 Transcription factor Proteins 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 208000027139 infectious colitis Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 18
- 238000009472 formulation Methods 0.000 abstract description 16
- 210000000813 small intestine Anatomy 0.000 abstract description 5
- 239000002775 capsule Substances 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 210000002429 large intestine Anatomy 0.000 abstract 3
- 238000009434 installation Methods 0.000 abstract 1
- 230000002028 premature Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 9
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 8
- 210000000981 epithelium Anatomy 0.000 description 8
- 230000003321 amplification Effects 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 230000000112 colonic effect Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000036457 multidrug resistance Effects 0.000 description 6
- 241000792859 Enema Species 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 239000007920 enema Substances 0.000 description 5
- 229940095399 enema Drugs 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 208000009326 ileitis Diseases 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 229920003136 Eudragit® L polymer Polymers 0.000 description 3
- 229920003134 Eudragit® polymer Polymers 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 229920003137 Eudragit® S polymer Polymers 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 2
- 206010016717 Fistula Diseases 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 2
- 238000012321 colectomy Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003890 fistula Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 1
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 229920003141 Eudragit® S 100 Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108700041567 MDR Genes Proteins 0.000 description 1
- 101150066553 MDR1 gene Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- JHDYSXXPQIFFJZ-UHFFFAOYSA-N chembl1834961 Chemical class C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC=CC=2)=C1 JHDYSXXPQIFFJZ-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 201000008243 diversion colitis Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 238000002575 gastroscopy Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- -1 lipid compounds Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 208000004840 megacolon Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000004767 rumen Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19835526 | 1998-08-06 | ||
| DE19857750A DE19857750A1 (de) | 1998-08-06 | 1998-12-15 | Phosphatidylocholin als Arzneimittel mit schleimhautschützender Wirkung |
| DE19857750.8 | 1998-12-15 | ||
| DE19835526.2 | 1998-12-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000563262A Division JP2002522381A (ja) | 1998-08-06 | 1999-08-06 | 粘膜保護用医薬としてのホスファチジルコリン |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2011178786A true JP2011178786A (ja) | 2011-09-15 |
Family
ID=7876645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011050079A Pending JP2011178786A (ja) | 1998-08-06 | 2011-03-08 | 粘膜保護用医薬としてのホスファチジルコリン |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP2011178786A (de) |
| DE (2) | DE19857750A1 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102013014417A1 (de) | 2013-08-29 | 2015-03-05 | Klinipharm Gmbh | Schwammkollagen umfassende Zubereitungen mit definiertem in vivo-Freisetzungsprofil vor allem im Colon, deren Herstellung und Verwendung |
-
1998
- 1998-12-15 DE DE19857750A patent/DE19857750A1/de not_active Ceased
-
1999
- 1999-08-06 DE DE59907648T patent/DE59907648D1/de not_active Expired - Lifetime
-
2011
- 2011-03-08 JP JP2011050079A patent/JP2011178786A/ja active Pending
Non-Patent Citations (4)
| Title |
|---|
| JPN6009064165; Ｄｉｇｅｓｔｉｏｎ Ｖｏｌ．５３， Ｎｏ．１-２, 1992, ｐ．３５-４４ * |
| JPN6013020587; ＳＣＡＮＤＩＮＡＶＩＡＮ ＪＯＵＲＮＡＬ ＯＦ ＣＬＩＮＩＣＡＬ ＆ ＬＡＢＯＲＡＴＯＲＹ ＩＮＶＥＳＴＩＧＡＴＩＯＮ Ｖｏｌ．１８， Ｎｏ．３, 1966, ｐ．２６３-２６７ * |
| JPN6013020590; Ｃｅｌｌ Ｖｏｌ．８７, 1996, ｐ．５０７-５１７ * |
| JPN6013020593; ＦＥＢＳ Ｌｅｔｔｅｒｓ Ｖｏｌ．３５４, 1994, ｐ．２６３-２６６ * |
Also Published As
| Publication number | Publication date |
|---|---|
| DE19857750A1 (de) | 2000-02-24 |
| DE59907648D1 (de) | 2003-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080118493A1 (en) | Elevated Hedgehog Pathway Activity In Digestive System Tumors, And Methods Of Treating Digestive Sytem Tumors Having Elevated Hedgehog Pathway Activity | |
| PT1272665E (pt) | Composições e métodos para identificar e alcançar células de cancro provenientes do tubo digestivo | |
| Burt | Inheritance of colorectal cancer | |
| WO2018022668A2 (en) | Neuromodulating compositions and related therapeutic methods for the treatment of cancer | |
| US20070231828A1 (en) | Methods of predicting behavior of cancers | |
| WO2005032343A2 (en) | Hedgehog signaling in prostate regeneration neoplasia and metastasis | |
| EP3160467B1 (de) | Kombination umfassend rifaximin und cyclosporin zur verwendung der behandlung des reizdarmsyndroms | |
| US20230135346A1 (en) | Oral rifamycin sv compositions | |
| JP2002522381A (ja) | 粘膜保護用医薬としてのホスファチジルコリン | |
| Strindberg et al. | Effect of supersaturation on absorption of indomethacin and tadalafil in a single pass intestinal perfusion rat model, in the absence and presence of a precipitation inhibitor | |
| Wenzel et al. | Organic cation transporter 1 an intestinal uptake transporter: fact or fiction? | |
| EP3218517B1 (de) | Mir-214 als diagnostischer und prognostischer spezifischer biomarker für colitis ulcerosa und mir-214-hemmer zur behandlung von colitis ulcerosa und kolitis-assoziierter kolorektaler krebs | |
| Chen et al. | Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress | |
| CN107326067B (zh) | 一种非酒精性脂肪肝的miRNA标记物 | |
| JP2011178786A (ja) | 粘膜保護用医薬としてのホスファチジルコリン | |
| US9404927B2 (en) | Systems and methods for diagnosing and treating cancer | |
| ES3018607T3 (es) | Tricostatina A para el uso en el tratamiento del mieloma múltiple | |
| EP3383406A1 (de) | Zusammensetzungen mit decitabin, 5azacytidin und tetrahydrouridin und verwendungen davon | |
| AU2022378576A1 (en) | Endoxifen for treatment of cancers | |
| Hu et al. | Alnustone Ameliorates Metabolic Dysfunction‐Associated Steatotic Liver Disease by Facilitating Mitochondrial Fatty Acid β‐Oxidation via Targeting Calmodulin | |
| Yamamoto et al. | Influence of pharmaceutical formulation on the mucosal concentration of 5-aminosalicylic acid and N-acetylmesalamine in Japanese patients with ulcerative colitis | |
| CN119318706A (zh) | Nr3a作为蛋白靶点在筛选或制备预防和/或治疗抑郁样行为的药物中的应用 | |
| CN114525342B (zh) | Linc02806在肝细胞癌诊断和治疗中的应用 | |
| CN111363824A (zh) | 一种用于肝癌诊断的lncRNA生物标志物及其应用 | |
| Mo et al. | Targeting FAM134B-DDX3X axis inhibiting AKT signaling in hepatocellular carcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110325 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110325 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20110518 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110518 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110609 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20120607 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120607 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130501 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130725 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130812 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131112 |